153 related articles for article (PubMed ID: 26689725)
1. Predicting analysis time in events-driven clinical trials using accumulating time-to-event surrogate information.
Wang J; Ke C; Yu Z; Fu L; Dornseif B
Pharm Stat; 2016 May; 15(3):198-207. PubMed ID: 26689725
[TBL] [Abstract][Full Text] [Related]
2. Predicting analysis time in event-driven clinical trials with event-reporting lag.
Wang J; Ke C; Jiang Q; Zhang C; Snapinn S
Stat Med; 2012 Apr; 31(9):801-11. PubMed ID: 22344853
[TBL] [Abstract][Full Text] [Related]
3. Joint monitoring and prediction of accrual and event times in clinical trials.
Zhang X; Long Q
Biom J; 2012 Nov; 54(6):735-49. PubMed ID: 22907686
[TBL] [Abstract][Full Text] [Related]
4. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
5. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
Jiang Z; Song Y; Shou Q; Xia J; Wang W
Trials; 2014 Dec; 15():500. PubMed ID: 25528466
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity to censored-at-random assumption in the analysis of time-to-event endpoints.
Lipkovich I; Ratitch B; O'Kelly M
Pharm Stat; 2016 May; 15(3):216-29. PubMed ID: 26997353
[TBL] [Abstract][Full Text] [Related]
8. Surrogate endpoints for overall survival in lung cancer trials: a review.
Fiteni F; Westeel V; Bonnetain F
Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
[TBL] [Abstract][Full Text] [Related]
9. Adaptive parametric prediction of event times in clinical trials.
Lan Y; Heitjan DF
Clin Trials; 2018 Apr; 15(2):159-168. PubMed ID: 29376735
[TBL] [Abstract][Full Text] [Related]
10. Endpoints in cancer clinical trials.
Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
[TBL] [Abstract][Full Text] [Related]
11. Milestone prediction for time-to-event endpoint monitoring in clinical trials.
Ou FS; Heller M; Shi Q
Pharm Stat; 2019 Jul; 18(4):433-446. PubMed ID: 30806485
[TBL] [Abstract][Full Text] [Related]
12. Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.
Aprile G; Fontanella C; Bonotto M; Rihawi K; Lutrino SE; Ferrari L; Casagrande M; Ongaro E; Berretta M; Avallone A; Rosati G; Giuliani F; Fasola G
Oncotarget; 2015 Oct; 6(30):28716-30. PubMed ID: 26308250
[TBL] [Abstract][Full Text] [Related]
13. Weibull prediction of event times in clinical trials.
Ying GS; Heitjan DF
Pharm Stat; 2008; 7(2):107-20. PubMed ID: 17377932
[TBL] [Abstract][Full Text] [Related]
14. Joint modeling of progression-free survival and overall survival by a Bayesian normal induced copula estimation model.
Fu H; Wang Y; Liu J; Kulkarni PM; Melemed AS
Stat Med; 2013 Jan; 32(2):240-54. PubMed ID: 22806764
[TBL] [Abstract][Full Text] [Related]
15. Predicting events in clinical trials using two time-to-event outcomes.
Mu R; Xu J
Biom J; 2018 Jul; 60(4):815-826. PubMed ID: 29790186
[TBL] [Abstract][Full Text] [Related]
16. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.
Ciani O; Davis S; Tappenden P; Garside R; Stein K; Cantrell A; Saad ED; Buyse M; Taylor RS
Int J Technol Assess Health Care; 2014 Jul; 30(3):312-24. PubMed ID: 25308694
[TBL] [Abstract][Full Text] [Related]
17. Interim decision-making strategies in adaptive designs for population selection using time-to-event endpoints.
Uozumi R; Hamada C
J Biopharm Stat; 2017; 27(1):84-100. PubMed ID: 26881477
[TBL] [Abstract][Full Text] [Related]
18. An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-event surrogate endpoints which comprise of one or more events of interest.
Dimier N; Todd S
Pharm Stat; 2017 Sep; 16(5):322-333. PubMed ID: 28544622
[TBL] [Abstract][Full Text] [Related]
19. Predicting event times in clinical trials when randomization is masked and blocked.
Donovan JM; Elliott MR; Heitjan DF
Clin Trials; 2007; 4(5):481-90. PubMed ID: 17942464
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
